Mariner’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $355K | Sell |
3,924
-70
| -2% | -$6.42K | ﹤0.01% | 2729 |
|
|
2025
Q4 | $359K | Sell |
3,994
-25,213
| -86% | -$2.39M | ﹤0.01% | 2696 |
|
|
2025
Q3 | $2.88M | Sell |
29,207
-1,444
| -5% | -$143K | ﹤0.01% | 1213 |
|
|
2025
Q2 | $2.8M | Buy |
30,651
+3,208
| +12% | +$310K | ﹤0.01% | 1144 |
|
|
2025
Q1 | $3.11M | Buy |
27,443
+265
| +1% | +$28.3K | 0.01% | 1002 |
|
|
2024
Q4 | $2.87M | Sell |
27,178
-801
| -3% | -$85.9K | ﹤0.01% | 1032 |
|
|
2024
Q3 | $3.02M | Sell |
27,979
-3,515
| -11% | -$384K | 0.01% | 989 |
|
|
2024
Q2 | $3.42M | Buy |
31,494
+15
| +0% | +$1.77K | 0.01% | 874 |
|
|
2024
Q1 | $4.15M | Buy |
31,479
+8,697
| +38% | +$1.09M | 0.01% | 800 |
|
|
2023
Q4 | $2.77M | Sell |
22,782
-14,399
| -39% | -$1.61M | 0.01% | 915 |
|
|
2023
Q3 | $4.17M | Sell |
37,181
-2,508
| -6% | -$318K | 0.01% | 703 |
|
|
2023
Q2 | $5.78M | Sell |
39,689
-4,067
| -9% | -$553K | 0.02% | 601 |
|
|
2023
Q1 | $5.65M | Buy |
43,756
+11,133
| +34% | +$1.4M | 0.02% | 595 |
|
|
2022
Q4 | $4.16M | Sell |
32,623
-143
| -0.4% | -$16.6K | 0.01% | 668 |
|
|
2022
Q3 | $3.43M | Buy |
32,766
+3,864
| +13% | +$424K | 0.01% | 612 |
|
|
2022
Q2 | $3.04M | Sell |
28,902
-28,746
| -50% | -$3.41M | 0.01% | 601 |
|
|
2022
Q1 | $7.37M | Sell |
57,648
-62,201
| -52% | -$7.5M | 0.03% | 407 |
|
|
2021
Q4 | $14.8M | Sell |
119,849
-25,420
| -17% | -$3.33M | 0.06% | 248 |
|
|
2021
Q3 | $20.6M | Buy |
145,269
+10,601
| +8% | +$1.56M | 0.11% | 193 |
|
|
2021
Q2 | $21M | Sell |
134,668
-126,336
| -48% | -$20.5M | 0.13% | 169 |
|
|
2021
Q1 | $40.6M | Sell |
261,004
-5,466
| -2% | -$847K | 0.28% | 102 |
|
|
2020
Q4 | $39.9M | Buy |
266,470
+6,979
| +3% | +$986K | 0.31% | 98 |
|
|
2020
Q3 | $34.3M | Buy |
259,491
+481
| +0.2% | +$62.8K | 0.32% | 91 |
|
|
2020
Q2 | $30M | Sell |
259,010
-2,492
| -1% | -$287K | 0.3% | 98 |
|
|
2020
Q1 | $25.7M | Sell |
261,502
-6,538
| -2% | -$857K | 0.32% | 90 |
|
|
2019
Q4 | $39M | Buy |
268,040
+2,444
| +0.9% | +$337K | 0.4% | 74 |
|
|
2019
Q3 | $35.4M | Buy |
265,596
+86,451
| +48% | +$11.2M | 0.42% | 67 |
|
|
2019
Q2 | $20.5M | Sell |
179,145
-87,849
| -33% | -$10.3M | 0.24% | 112 |
|
|
2019
Q1 | $22.2M | Buy |
266,994
+257,664
| +2,762% | +$29.3M | 0.32% | 92 |
|
|
2018
Q4 | $940K | Buy |
9,330
+7,133
| +325% | +$802K | 0.02% | 447 |
|
|
2018
Q3 | $280K | Buy |
2,197
+16
| +0.7% | +$1.9K | 0.01% | 675 |
|
|
2018
Q2 | $236K | Sell |
2,181
-387
| -15% | -$42.1K | 0.01% | 705 |
|
|
2018
Q1 | $272K | Buy |
+2,568
| New | +$298K | 0.01% | 543 |
|
|
2017
Q2 | – | Sell |
-2,094
| Closed | -$248K | – | 574 |
|
|
2017
Q1 | $248K | Buy |
2,094
+102
| +5% | +$11.6K | 0.01% | 502 |
|
|
2016
Q4 | $200K | Sell |
1,992
-1,206
| -38% | -$129K | 0.01% | 525 |
|
|
2016
Q3 | $404K | Buy |
3,198
+1,239
| +63% | +$153K | 0.02% | 408 |
|
|
2016
Q2 | $229K | Buy |
+1,959
| New | +$222K | 0.01% | 468 |
|
|
2015
Q4 | – | Sell |
-3,129
| Closed | -$285K | – | 563 |
|
|
2015
Q3 | $285K | Buy |
+3,129
| New | +$314K | 0.01% | 411 |
|
Other funds holding ZBH
VCM
VPM
Mariner's ZBH Position: Q1 2026 in Review
Mariner reduced its Zimmer Biomet (ZBH) stake by 1.8% in Q1 2026, selling an estimated $6.42K and leaving 3,924 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #2729.
Mariner first reported a position in ZBH in Q3 2015 and has held it in 38 quarters since. The position peaked at $40.6M in Q1 2021. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.
- Mariner held 3,924 shares of Zimmer Biomet worth $355K as of Q1 2026.
- Mariner sold 70 Zimmer Biomet shares in Q1 2026, an estimated $6.42K.
- Zimmer Biomet made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2729 holding.
- Mariner first reported a position in Zimmer Biomet in Q3 2015 and has held it in 38 quarters since.
- Mariner's Zimmer Biomet position peaked at $40.6M in Q1 2021.
- 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.
Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.